Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Idiopathic Pulmonary Fibrosis Condition: Initial dose titration |
Dose: Capsule – 267 mg (1 capsule) Frequency: three times daily by mouth Duration: Days 1-7 |
|
Indication: Idiopathic Pulmonary Fibrosis Condition: Initial dose titration |
Dose: Capsule – 534 mg (2 capsules) Frequency: three times daily by mouth Duration: Days 8-14 |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild, moderate, or severe renal impairment |
Dose: Not specified Note: Use caution; monitor and consider dosage modification or discontinuation as needed |
|
Condition: End-stage renal disease requiring dialysis |
Dose: Not specified Note: No recommended (not studied) |
Administration
- Take with food
- Take at same time each day
Side Effect
- Nausea (36%)
- Rash (30%)
- Upper respiratory tract infection (URTI) (27%)
- Diarrhea (26%)
- Abdominal pain (24%)
- Headache (22%)
- Dyspepsia (19%)
- Dizziness (18%)
- Vomiting (13%)
- GERD (11%)
- Sinusitis (11%)
- Insomnia (10%)
- Weight decreased (10%)
- Arthralgia (10%)
- Photosensitivity (9%)
- Decreased appetite (8%)
- Pruritus (8%)
- Asthenia (6%)
- Dysgeusia (6%)
- Noncardiac chest pain (5%)
- AST/ALT ≥3 x ULN (3.7%)
- AST/ALT ≥10 x ULN (0.3%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Grapefruit juice
|
Inhibition of CYP1A2
|
|
Fluvoxamine, other strong & selective CYP1A2 inhibitors, ciprofloxacin, amiodarone, propafenone
|
Increased exposure
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Hepatic Impairment
|
Risk of liver complications
|
|
End Stage Renal Disease
|
Risk of drug accumulation
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool and dry place, protected from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.